相关实验视频

Updated: May 20, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K

对法里西马布的不良事件报告:对FDA不良事件报告系统 (FAERS) 数据库的不成比例分析

Chang-Zhu He1, Qin Qiu1, Song-Jie Lu1

  • 1Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.

Frontiers in pharmacology
|March 27, 2025
PubMed
概括

法里西马布 (Faricimab) 是一种对视网膜疾病的双特异性抗体,在现实数据中显示了不良事件,包括已知的和新的安全问题,如失明. 临床医生应密切监测患者的潜在副作用.

关键词:
在FAERS数据库中,我们可以找到FAERS数据库.不良事件不良事件不良事件这是不成比例的不成比例.法里西马布 (法里西马布) 是一个法里西马布 (法里西马布)药物监督和药物监督

更多相关视频

FRET Imaging in Three-dimensional Hydrogels09:47

FRET Imaging in Three-dimensional Hydrogels

Published on: August 1, 2016

13.0K
Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles08:02

Isolation of Primary Cancer-Associated Fibroblasts from a Syngeneic Murine Model of Breast Cancer for the Study of Targeted Nanoparticles

Published on: May 14, 2021

5.4K

相关概念视频

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
72